-
Something wrong with this record ?
The barrier function of organotypic non-melanoma skin cancer models
C. Zoschke, M. Ulrich, M. Sochorová, C. Wolff, K. Vávrová, N. Ma, C. Ulrich, JM. Brandner, M. Schäfer-Korting,
Language English Country Netherlands
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Diterpenes pharmacology MeSH
- Esterases metabolism MeSH
- Fibroblasts metabolism MeSH
- Keratinocytes metabolism MeSH
- Caffeine pharmacology MeSH
- Coculture Techniques MeSH
- Skin drug effects metabolism MeSH
- Humans MeSH
- Lipid Metabolism MeSH
- Cell Line, Tumor MeSH
- Skin Neoplasms metabolism MeSH
- Tight Junction Proteins metabolism MeSH
- Cell Survival drug effects MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Non-melanoma skin cancer (NMSC) is the most frequent human cancer with continuously rising incidences worldwide. Herein, we investigated the molecular basis for the impaired skin barrier function of organotypic NMSC models. We unraveled disturbed epidermal differentiation by reflectance confocal microscopy and histopathological evaluation. While the presence of claudin-4 and occludin were distinctly reduced, zonula occludens protein-1 was more wide-spread, and claudin-1 was heterogeneously distributed within the NMSC models compared with normal reconstructed human skin. Moreover, the cancer altered stratum corneum lipid packing and profile with decreased cholesterol content, increased phospholipid amount, and altered ceramide subclasses. These alterations contributed to increased surface pH and to 1.5 to 2.6-fold enhanced caffeine permeability of the NMSC models. Three topical applications of ingenol mebutate gel (0.015%) caused abundant epidermal cell necrosis, decreased Ki-67 indices, and increased lactate dehydrogenase activity. Taken together, our study provides new biological insights into the microenvironment of organotypic NMSC models, improves the understanding of the disease model by revealing causes for impaired skin barrier function in NMSC models at the molecular level, and fosters human cell-based approaches in preclinical drug evaluation.
Collegium Medicum Berlin Luisenstr 54 10117 Berlin Germany
Institute for Pharmacy Freie Universität Berlin Königin Luise Str 2 4 14195 Berlin Germany
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18017282
- 003
- CZ-PrNML
- 005
- 20180515103126.0
- 007
- ta
- 008
- 180515s2016 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jconrel.2016.04.037 $2 doi
- 035 __
- $a (PubMed)27130695
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Zoschke, Christian $u Institute for Pharmacy, Freie Universität Berlin, Königin-Luise-Str. 2+4, 14195 Berlin, Germany.
- 245 14
- $a The barrier function of organotypic non-melanoma skin cancer models / $c C. Zoschke, M. Ulrich, M. Sochorová, C. Wolff, K. Vávrová, N. Ma, C. Ulrich, JM. Brandner, M. Schäfer-Korting,
- 520 9_
- $a Non-melanoma skin cancer (NMSC) is the most frequent human cancer with continuously rising incidences worldwide. Herein, we investigated the molecular basis for the impaired skin barrier function of organotypic NMSC models. We unraveled disturbed epidermal differentiation by reflectance confocal microscopy and histopathological evaluation. While the presence of claudin-4 and occludin were distinctly reduced, zonula occludens protein-1 was more wide-spread, and claudin-1 was heterogeneously distributed within the NMSC models compared with normal reconstructed human skin. Moreover, the cancer altered stratum corneum lipid packing and profile with decreased cholesterol content, increased phospholipid amount, and altered ceramide subclasses. These alterations contributed to increased surface pH and to 1.5 to 2.6-fold enhanced caffeine permeability of the NMSC models. Three topical applications of ingenol mebutate gel (0.015%) caused abundant epidermal cell necrosis, decreased Ki-67 indices, and increased lactate dehydrogenase activity. Taken together, our study provides new biological insights into the microenvironment of organotypic NMSC models, improves the understanding of the disease model by revealing causes for impaired skin barrier function in NMSC models at the molecular level, and fosters human cell-based approaches in preclinical drug evaluation.
- 650 _2
- $a kofein $x farmakologie $7 D002110
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a kokultivační techniky $7 D018920
- 650 _2
- $a diterpeny $x farmakologie $7 D004224
- 650 _2
- $a esterasy $x metabolismus $7 D004950
- 650 _2
- $a fibroblasty $x metabolismus $7 D005347
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a keratinocyty $x metabolismus $7 D015603
- 650 _2
- $a metabolismus lipidů $7 D050356
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a kůže $x účinky léků $x metabolismus $7 D012867
- 650 _2
- $a nádory kůže $x metabolismus $7 D012878
- 650 _2
- $a proteiny těsného spoje $x metabolismus $7 D062725
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ulrich, Martina $u Collegium Medicum Berlin, Luisenstr. 54, 10117 Berlin, Germany; Department of Dermatology, Venereology and Allergology, Skin Cancer Center Charité, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
- 700 1_
- $a Sochorová, Michaela $u Faculty of Pharmacy, Charles University in Prague, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic.
- 700 1_
- $a Wolff, Christopher $u Institute for Pharmacy, Freie Universität Berlin, Königin-Luise-Str. 2+4, 14195 Berlin, Germany.
- 700 1_
- $a Vávrová, Kateřina $u Faculty of Pharmacy, Charles University in Prague, Akademika Heyrovského 1203, 50005 Hradec Králové, Czech Republic.
- 700 1_
- $a Ma, Nan $u Institute of Biomaterial Science, Department of Biocompatibility, Helmholtz Centre for Materials and Coastal Research, Kantstr. 55, 14153 Teltow, Germany.
- 700 1_
- $a Ulrich, Claas $u Department of Dermatology, Venereology and Allergology, Skin Cancer Center Charité, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
- 700 1_
- $a Brandner, Johanna M $u Department of Dermatology and Venereology, University Hospital Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.
- 700 1_
- $a Schäfer-Korting, Monika $u Institute for Pharmacy, Freie Universität Berlin, Königin-Luise-Str. 2+4, 14195 Berlin, Germany. Electronic address: monika.schaefer-korting@fu-berlin.de.
- 773 0_
- $w MED00002621 $t Journal of controlled release official journal of the Controlled Release Society $x 1873-4995 $g Roč. 233, č. - (2016), s. 10-8
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27130695 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180515103259 $b ABA008
- 999 __
- $a ok $b bmc $g 1300906 $s 1014122
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 233 $c - $d 10-8 $e 20160427 $i 1873-4995 $m Journal of controlled release $n J Controlled Release $x MED00002621
- LZP __
- $a Pubmed-20180515